Cancer clinical pharmacology by Jan H. M. SchellensCancer clinical pharmacology by Jan H. M. Schellens

Cancer clinical pharmacology

EditorJan H. M. Schellens, Howard L. Mcleod, David R. Newell

Hardcover | March 21, 2005

Pricing and Purchase Info

$315.00 online 
$360.00 list price save 12%
Earn 1575 plum® points
Quantity:

Ships within 1-3 weeks

Ships free on orders over $25

Not available in stores

about

Cancer Clinical Pharmacology provides a comprehensive account of the scientific basis of anti-cancer therapy in patients with solid tumours and haematological malignancies. An international group of experts have brought together information on the basic principles of pharmacology and tumourbiology, bioanalytical aspects, pharmacokinetics, and the pharmacodynamics of anti-cancer agents. The clinical pharmacology of individual anti-cancer agents are covered, including the most important recently registered novel anti-cancer drugs. This book will prove an invaluable source of information for all trainees in oncology, haematology and internal medicine. Since cancer clinical pharmacology is a vast subject this book will be useful for all individuals involved in cancer pharmacology such as nurses, pharmacists, generalpharmacologists, and cancer scientists.
Jan H M Schellens is a Consultant Medical Oncologist and Clinical Pharmacologist, The Netherlands Cancer Institute, Amsterdam and the Faculty of Pharmaceutical Sciences, Division of Drug Toxicology, University Utrecht, Utrecht, The Netherlands. Howard McLeod is an Associate Professor, Washington University School of Medicine, St. Louis...
Loading
Title:Cancer clinical pharmacologyFormat:HardcoverDimensions:280 pages, 9.69 × 7.44 × 0.81 inPublished:March 21, 2005Publisher:Oxford University PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0192629662

ISBN - 13:9780192629661

Reviews

Table of Contents

1. Jos H. Beijnen and Hilde Rosing: Bio-analytical methods for anticancer drugs2. Etienne Chatelut: Principles of pharmacokinetics3. Jan H. M. Schellens: Clinical implications and mechanisms of variability in the response to anticancer agents4. Jim Cassidy: Drug development and study design5. Gerard Milano and Jan H. M. Schellens: Pyrimidine antimetabolites6. Jan Liliemark and Curt Peterson: Purine analogs and antifolates7. Alan V. Boddy: Alkylating agents8. Howard L. McLeod: Epipodophyllotoxins9. Jacques Robert: Anthracyclines10. Lucia Vigano, Alberta Locatelli and Luca Gianni: Taxanes11. Timothy W. Synold: Vinca alkaloids12. Eric K. Rowinsky and Sharyn D. Baker: Topoisomerase I targeting agents13. Steven W. Johnson, James P. Stevenson and Peter J. O'Dwyer: Platinum agents14. Wandena S. Lakhai, Jos H. Beijnen and Jan H. M. Schellens: Novel tyrosine kinase inhibitors: focus on Imatinib and Gefitinib15. Per E. Lonning: Antiendoctrine drugs used in cancer treatment16. D. Paul Harkin and Patrick G. Johnston: The clinical application of tumour biology